Tandem Diabetes (TNDM) Misses Q3 EPS by 28c, Revenues Beat; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Tandem Diabetes Care Reports Third Quarter 2018 Financial Results
November 1, 2018 4:05 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.
Third Quarter 2018 Results
In comparing the third quarter of 2018 to the same period of 2017:
Pump shipments increased 118 percent to 8,434 pumps from 3,868 pumps Sales increased 71 percent to $46.3 million from $27.0 million Operating margin improved to negative 34 percent from negative 49 percentWe delivered a record-setting quarter in terms of robust... More
